Cargando…

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer

SIMPLE SUMMARY: Epithelial to mesenchymal transition (EMT) is a mechanism endowing tumor cells with aggressive properties and escape immune surveillance. Here, we reported that activating EMT process in breast cancer cells upregulates CMTM6, an essential protein required for cell surface expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Malina, Hasmim, Meriem, Lequeux, Audrey, Moer, Kris Van, Tan, Tuan Zea, Gilles, Christine, Hollier, Brett G., Thiery, Jean Paul, Berchem, Guy, Janji, Bassam, Noman, Muhammad Zaeem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963182/ https://www.ncbi.nlm.nih.gov/pubmed/33803139 http://dx.doi.org/10.3390/cancers13051165

Ejemplares similares

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges
por: Noman, Muhammad Zaeem, et al.
Publicado: (2019)

Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy
por: Lequeux, Audrey, et al.
Publicado: (2021)

SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC
por: Hasmim, Meriem, et al.
Publicado: (2022)

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
por: Noman, Muhammad Zaeem, et al.
Publicado: (2020)

Firing up the cold tumors by targeting Vps34
por: Janji, Bassam, et al.
Publicado: (2020)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies
por: Xiao, Malina, et al.
Publicado: (2021)

Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34
por: Janji, Bassam, et al.
Publicado: (2020)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

A role for EMT in CD73 regulation in breast cancer
por: Hasmim, Meriem, et al.
Publicado: (2022)

The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation
por: Noman, Muhammad Zaeem, et al.
Publicado: (2022)

The multifaceted role of autophagy in tumor evasion from immune surveillance
por: Janji, Bassam, et al.
Publicado: (2016)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet
por: Viry, Elodie, et al.
Publicado: (2016)

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
por: Noman, Muhammad Zaeem, et al.
Publicado: (2014)

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target
por: Noman, Muhammad Zaeem, et al.
Publicado: (2018)

CMTM8 inhibits the carcinogenesis and progression of bladder cancer
por: GAO, DENGHUI, et al.
Publicado: (2015)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review
por: Li, Jie, et al.
Publicado: (2022)

Expression of CMTM4 shows clinical significance in lung cancer
por: Zhu, Xiaonian, et al.
Publicado: (2020)

Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
por: Tan, Shengkui, et al.
Publicado: (2022)

CMTM3 as a Potential New Immune Checkpoint Regulator
por: Shen, Qian, et al.
Publicado: (2022)

Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma
por: Pei, Yulin, et al.
Publicado: (2023)

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
por: Giuliani, Massimo, et al.
Publicado: (2017)

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer
por: Zhang, Chao, et al.
Publicado: (2021)

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer
por: Tian, Yiping, et al.
Publicado: (2021)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

Schwann-cell-derived CMTM6 restricts radial axonal growth
por: Elazar, Nimrod, et al.
Publicado: (2020)

Progressive axonopathy when oligodendrocytes lack the myelin protein CMTM5
por: Buscham, Tobias J, et al.
Publicado: (2022)

MARVEL domain containing CMTM4 affects CXCR4 trafficking
por: Bona, Alexandra, et al.
Publicado: (2022)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
por: Yugawa, Kyohei, et al.
Publicado: (2020)

Identification of CMTM7 as a Transmembrane Linker of BLNK and the B-Cell Receptor
por: Miyazaki, Atsuko, et al.
Publicado: (2012)

Identification of Serum CMTM2 as a Potential Biomarker for HBV-Related Disorders
por: Chen, Shu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uenh3iuo1digcf26c4usjh8gr8